## SDGR: Schrodinger, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.4% below STRENGTH zone (4.0-10.0%); PEG 1.30 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($15.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.03M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-2.2%)
- Gates Foundation Tru: 10.8% (0.0%)
- Vanguard Group Inc: 9.8% (-4.2%)
- Rubric Capital Manag: 8.2% (+5.4%)
- Sumitomo Mitsui Trus: 7.1% (+24.8%)

### Key Risks

1. High short interest (24.7%, 8.0 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 19.3% below SMA200.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.30 suggests fair value with growth premium. Balance sheet: strong liquidity (3.2x). Revenue growth strong at 20% YoY. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 1.57 |
| 52W Range | $15.99 - $28.47 |
| Short Interest | 24.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.30 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -6.7% to -5.4% (+1.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 9.4pp (needs >4.0% for momentum thesis). AM_20 at -4.5% indicates price below own 20MA trend. Underperforming sector by 6.8pp, stock-specific weakness. Below SMA200 (0.81x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.43% (CS: 9) | Weak |
| RSI_14 | 39.6 | Neutral |
| MACD Histogram | 0.04 | Bullish |
| vs SMA20 | 0.955x | Below |
| vs SMA50 | 0.876x | Below |
| vs SMA200 | 0.807x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $17.04
- **Stop Loss:** $15.28 (10.3% risk)
- **Target:** $18.80 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 426
- **Position Value:** $7,259.04
- **Portfolio %:** 7.26%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-25 (Est: $-0.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.74 | $-0.57 | +23.0% |
| 2025Q2 | $-0.64 | $-0.65 | -1.6% |
| 2025Q1 | $-0.81 | $-0.64 | +21.0% |
| 2024Q4 | $-0.38 | $-0.24 | +36.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*